Results 51 to 60 of about 31,914 (284)

Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. [PDF]

, 2018
© 2018 Vimalesvaran et al. This work is published and licensed by Dove Medical Press Limited.Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it leads to significant morbidity and mortality, predominantly from ischemic stroke.
Dockrill, Seth J, Gorog, Diana, Vimalesvaran, Kavitha   +2 more
core   +3 more sources

Comparative Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients

Stroke, 2021
Supplemental Digital Content is available in the text. Background and Purpose: Several observational studies have compared the effect of the non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation.
Wengen Zhu, Zi Ye, Shilan Chen, Dexi Wu, Jiangui He, Yugang Dong, G. Lip, Chen Liu   +7 more
semanticscholar   +1 more source

Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality

Global Heart, 2020
Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for
Ezequiel J. Zaidel, Xinyi Leng, Abiodun Moshood Adeoye, Ferdous Hakim, Biraj Karmacharya, Asim Katbeh, Lis Neubeck, Stephanie Partridge, Pablo Perel, Mark D. Huffman, Mariachiara Di Cesare   +10 more
doaj   +1 more source

Safety and Efficacy of Double Antithrombotic Therapy With Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020
Background The optimal antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention is a topic of debate. We aimed at defining the efficacy and safety of double antithrombotic therapy with single antiplatelet
D. Capodanno, M. Di Maio, A. Greco, Deepak L. Bhatt, C. Gibson, A. Goette, R. Lopes, R. Mehran, P. Vranckx, D. Angiolillo   +9 more
semanticscholar   +1 more source

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios

International Journal of Cardiology: Heart & Vasculature, 2018
Atrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia.
Ting-Yung Chang, Jo-Nan Liao, Tze-Fan Chao, Jennifer Jeanne Vicera, Chin-Yu Lin, Ta-Chuan Tuan, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Fa-Po Chung, Shih-Ann Chen   +11 more
doaj   +1 more source

Comparison Between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism

JAMA Network Open, 2021
This cohort study compares the risks of venous thromboembolism (VTE) recurrence in patients receiving non–vitamin K antagonist oral anticoagulants (NOACs) vs low-molecular-weight heparin in Asian individuals with cancer.
Dong-Yi Chen, Chi-Nan Tseng, M. Hsieh, Wen-Ching Lan, C. Chuang, S. Pang, Shao‐Wei Chen, Tien‐Hsing Chen, Shang-Hung Chang, I. Hsieh, P. Chu, M. Wen, Jen‐Shi Chen, J. Chang, L. See, Wen-Kuan Huang   +15 more
semanticscholar   +1 more source

Non–Vitamin K Antagonist Oral Anticoagulants: The Clinician’s New Challenge

Journal of Osteopathic Medicine, 2015
Abstract Millions of US patients are prescribed oral anticoagulants. Traditionally, oral anticoagulation was achieved with vitamin K antagonists (VKAs). In recent years, non–VKA oral anticoagulants (NOACs) have emerged that provide an effective and convenient alternative to VKAs.
Brian K, Yorkgitis, Jeanette, Zhang, Joseph F, Rappold   +2 more
openaire   +2 more sources

State of play and future direction with NOACs: An expert consensus. [PDF]

, 2018
Atrial fibrillation (AF) and venous thromboembolism (VTE) are cardiovascular conditions significant in contemporary practice. In both, the use of anticoagulation with vitamin K antagonists (VKAs) has been traditionally used to prevent adverse events ...
A.J. Camm, A.T. Cohen, Ageno, Agnelli, Alings, Ansell, Ansell, Apostolakis, Avgil-Tsadok, Beyer-Westendorf, Beyer-Westendorf, Beyer-Westendorf, Bohula, Bouillon, Brunner-Ziegler, Caldeira, Caldeira, Camm, Cannon, Cohen, Cohen, Coleman, Connolly, Connolly, Connolly, Cronin-Fenton, De Caterina, De Caterina, De Caterina, De Caterina, Diener, Diener, Diener, Douketis, Easton, Eikelboom, Ensor, F. Verheugt, Fang, Fauchier, Forslund, Fox, Friberg, Friberg, Furugohri, G. Agnelli, G.Y. Lip, Gage, Gibson, Giugliano, Glund, Granger, Gross, Guo, H. Heidbuchel, Hankey, Heidbuchel, Heidbuchel, Heit, Heit, Hijazi, Hohnloser, Husted, Investigators, J.L. Zamorano, Kearon, Keeling, Khorana, Kirchhof, Kooiman, Kooistra, Larsen, Levy, Lip, Lip, Lip, Lip, Lip, Lublóy, Martinez, Masjuan, Mendell, Mendell, Miyasaka, Moore, Morgan, Mungall, Murphy, Márquez-Contreras, Nielsen, Oldgren, Paciaroni, Paciaroni, Patel, Perzborn, Peterson, Pinto, Pollack, Pollack, Price, Prins, Proietti, Proietti, R. De Caterina, Raskob, Renda, Roffi, Roldán, Ruff, Ruff, Sandén, Sardar, Sardar, Sarich, Schulman, Schulman, Senoo, Senoo, Shekelle, Sjögren, Song, Stacy, Stampfuss, Stangier, Steinberg, Tafur, The EINSTEIN investigators, The EINSTEIN–PE Investigators, van der Hulle, van Walraven, Verhamme, Vrijens, Watanabe, Weitz, Wolf, Zamorano   +135 more
core   +5 more sources

Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2017
Background The original non–vitamin K antagonist oral anticoagulant (NOAC) trials in nonvalvular atrial fibrillation (AF) enrolled patients with native valve pathologies.
K. Pan, D. Singer, B. Ovbiagele, Yi-Ling Wu, Mohamed A. Ahmed, Meng Lee   +5 more
semanticscholar   +1 more source

Off-Label Use of Non-Vitamin K Antagonist Oral Anticoagulants

Journal of the American College of Cardiology, 2017
In their report, Steinberg et al. [(1)][1] nicely demonstrate that despite the advantage of uniform non-vitamin K antagonist oral anticoagulants (NOAC) dosing, off-label treatment occurs in approximately 13% of patients, which is related to adverse outcomes.
Vugt, S.P.G. van, Brouwer, M.A., Verheugt, F.W.A.   +2 more
openaire   +4 more sources